Interleukin‐17 receptor <scp>A</scp> blockade with brodalumab in palmoplantar pustular psoriasis: Report on four cases

Pinter, Andreas; Wilsmann‐Theis, Dagmar; Peitsch, Wiebke K.; Mößner, Rotraut

doi:10.1111/1346-8138.14815

Cited by 20 publications

(19 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the IL-17 inhibitors, secukinumab and brodalumab have been investigated for the treatment of PPP [108,109]. In a multicenter, randomized, double-blind clinical trial (2PRECISE) involving over 200 patients with PPP, secukinumab 300 mg and 150 mg were compared with placebo in the treatment of PPP.…”

Section: Il-17 Inhibitorsmentioning

confidence: 99%

“…At week 52, a total of 41.8% of the patients receiving secukinumab 300 mg reached PPPASI-75, and 43.1% had a DLQI response of 0 or 1 [108]. A case series of four patients receiving brodalumab reported a lack of efficacy or moderate improvement in the treatment of PPP [109]. A phase III placebo-controlled study on the efficacy of brodalumab in subjects with PPP is ongoing ( Table 2).…”

Section: Il-17 Inhibitorsmentioning

confidence: 99%

See 1 more Smart Citation

Palmoplantar Pustulosis: Recent Advances in Etiopathogenesis and Emerging Treatments

2020

View full text Add to dashboard Cite

Palmoplantar pustulosis (PPP) is a chronic, recurrent skin disease belonging to the spectrum of psoriasis. It is characterized by an eruption of sterile pustules on the palms and soles. Recent studies in PPP have focused on genetic differences between pustular phenotypes and the role of the innate immunological system and the microbiome in the etiopathogenesis of the disease. Mutations in IL36RN (a major predisposing factor for generalized pustular psoriasis) were found in selected patients with PPP and were associated with earlier disease onset. Studies have shown that the interleukin (IL)-17 and IL-36 pathways might be involved in the pathogenesis of PPP. A microbiome has been demonstrated in the vesicopustules of PPP, and an abundance of Staphylococcus appears to be increased by smoking. Improved understanding of the underlying etiopathogenesis of PPP has led to advances in treatment options, and targeted therapies for PPP have been evaluated or are under evaluation against more than 12 molecules in ongoing clinical trials.

show abstract

Section: Il-17 Inhibitorsmentioning

confidence: 99%

Section: Il-17 Inhibitorsmentioning

confidence: 99%

Palmoplantar Pustulosis: Recent Advances in Etiopathogenesis and Emerging Treatments

2020

View full text Add to dashboard Cite

show abstract

“…The IL-17 inhibitor secukinumab has also been evaluated for moderate-to-severe PPP, but did not demonstrate superiority versus placebo in achievement of the primary endpoint (75% improvement from baseline in Palmoplantar Pustulosis Psoriasis Area and Severity Index [PPPASI]) [54]. Brodalumab, another IL-17 inhibitor, has been evaluated in PPP and has demonstrated either no improvement or moderate improvement in a recent case series of treated patients [55]. A small (N = 15), randomized, placebo-controlled, prospective study of a TNFa inhibitor, etanercept, has shown mixed results, with some patients experiencing improvements and others showing worsening PPP [56].…”

Section: Treatment Optionsmentioning

confidence: 99%

Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options

Menter

Voorhees

Hsu

2021

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Pustular psoriasis is an unusual form of psoriasis that frequently presents clinical challenges for dermatologists. The condition presents with pustules on an erythematous background and has two distinct subtypes: localized disease on the palms and soles, called palmoplantar pustulosis (PPP), and generalized pustular psoriasis (GPP). The involvement of the fingers, toes, and nails is defined as a separate localized variant, acrodermatitis continua of Hallopeau, and is now thought to be a subset of PPP. The rarity of pustular psoriasis frequently makes the correct diagnosis problematic. In addition, treatment is limited by a relative lack of evidence-based

show abstract

“…But, in the long-term, at week 52, non-responders of the secukinumab and the placebo arms were treated with 300 mg every 4 weeks with 42% PPPASI-75 efficacy and 150 mg with 35% PPPASI-75 efficacy 54 . Only case reports regarding other anti-IL-17 therapies are available, with lack of efficacy of brodalumab in four PPP cases, but a phase III RCT is ongoing 43 , 55 .…”

Section: New Therapeutic Optionsmentioning

confidence: 99%

Recent advances in palmoplantar pustulosis

Brunasso¹,

Massone²

2021

Fac Rev

View full text Add to dashboard Cite

Palmoplantar pustulosis (PPP) is a chronic inflammatory condition where crops of sterile pustules with erythematous keratotic lesions causing bleeding and pain appear on the palms and soles. Recently, the European Rare and Severe Expert Network considered PPP as a variant of pustular psoriasis with or without psoriasis vulgaris. The prevalence of PPP varies from 0.050 to 0.12%. PPP occurs more frequently in women and the highest prevalence occurred between the ages of 50 and 69 years. Nail psoriasis seems to be frequent in PPP, ranging from 30 to 76%, and psoriatic arthritis in 8.6 to 26% of PPP patients. Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome and pustulotic arthro-osteitis are considered PPP-associated disorders. PPP has been reported with other co-morbidities such as psychiatric disorders, thyroid-associated disease, altered calcium homeostasis, gluten sensitivity diabetes, obesity, and dyslipidemia, but larger studies are required to prove such associations. Environmental exacerbating factors might contribute to the onset or worsening of PPP such as cigarette smoking, stress, focal infections, metal allergies, and drug intake. Genetic predisposition plays an important role in PPP. In PPP, both the innate and the adaptive immune systems are activated. The acrosyringeal expression of IL-17 has been demonstrated, indicating that the eccrine sweat gland is an active component of the skin barrier and an immune-competent structure. Increased levels of several inflammatory molecules, including IL-8, IL-1α, IL-1β, IL-17A, IL-17C, IL-17D, IL-17F, IL-22, IL-23A, and IL-23 receptor, have been detected in PPP biopsies. Increased serum levels of TNF-α, IL-17, IL-22, and IFN-γ have been detected in patients with PPP in comparison to healthy subjects, suggesting a similar inflammatory pattern to psoriasis vulgaris. Oral and tonsillar infections serve as trigger factors for PPP. Long-term therapy is required for many patients, but high-quality data are limited, contributing to uncertainty about the ideal approach to treatment.

show abstract

Interleukin‐17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: Report on four cases

Cited by 20 publications

References 10 publications

Palmoplantar Pustulosis: Recent Advances in Etiopathogenesis and Emerging Treatments

Palmoplantar Pustulosis: Recent Advances in Etiopathogenesis and Emerging Treatments

Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options

Recent advances in palmoplantar pustulosis

Contact Info

Product

Resources

About